Preclinical development of a next-generation CAR-T cell therapy for multiple myeloma.

Multiple myeloma (MM) is an malignancy that remains incurable to date. Chimeric antigen receptor (CAR)-T cell therapy has obtainedimpressive clinical results in leukemia and lymphoma, and is gaining momentum in MM as well. This project aims to tackle shortcomings in efficacy and safety in current CAR-T cell therapies by targeting multiple MM antigens, reducing T cell exhaustion and exploring alternative T cell subsets. Importantly, transient T cell modification ensures patient safety, reduces manufacturing costs significantly and can serve as an early-phase testing platform for clinical translation of novel CAR-T cell therapies.

Keywords:CHIMERIC ANTIGEN RECEPTORS, IMMUNOTHERAPY, MULTIPLE MYELOMA

Disciplines:Hematology, Applied immunology, Cancer therapy